Disease · MONDO_0006047
Comparisons in its trials113
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 113
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine: serious adverse events | 212 of 421 | 172 of 402 | 823 | NCT00844649 | Trial comparisons |
| NALIRIFOX vs Nab-paclitaxel+Gemcitabine: deaths from any cause | 345 of 370 | 359 of 379 | 749 | NCT04083235 | Trial comparisons |
| NALIRIFOX vs Nab-paclitaxel+Gemcitabine: serious adverse events | 207 of 370 | 198 of 379 | 749 | NCT04083235 | Trial comparisons |
| TH-302 vs Placebo: serious adverse events | 341 of 341 | 338 of 338 | 679 | NCT01746979 | Trial comparisons |
| Axitinib + Gemcitabine vs Placebo + Gemcitabine: serious adverse events | 108 of 304 | 102 of 309 | 613 | NCT00471146 | Trial comparisons |
| Pegilodecakin + FOLFOX vs FOLFOX: deaths from any cause | 217 of 278 | 188 of 251 | 529 | NCT02923921 | Trial comparisons |
| Pegilodecakin + FOLFOX vs FOLFOX: serious adverse events | 123 of 278 | 95 of 251 | 529 | NCT02923921 | Trial comparisons |
| CPI-613, mFolfirinox vs Folfirinox: Overall Response Rate (ORR) | 104 of 266 | 90 of 262 | 528 | NCT03504423 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Disease Control Rate (DCR) | 147 of 255 | 126 of 257 | 512 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Objective Response Rate (ORR) | 41 of 255 | 32 of 257 | 512 | NCT03665441 | Trial comparisons |
| CPI-613, mFolfirinox vs Folfirinox: deaths from any cause | 140 of 259 | 133 of 235 | 494 | NCT03504423 | Trial comparisons |
| CPI-613, mFolfirinox vs Folfirinox: serious adverse events | 140 of 259 | 133 of 235 | 494 | NCT03504423 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: deaths from any cause | 209 of 248 | 211 of 246 | 494 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 122 of 248 | 105 of 246 | 494 | NCT03665441 | Trial comparisons |
| Placebo (Plus Nab-paclitaxel and Gemcitabine) vs Ibrutinib (Plus Nab-paclitaxel and Gemcitabine): deaths from any cause | 188 of 212 | 189 of 208 | 420 | NCT02436668 | Trial comparisons |
| Placebo (Plus Nab-paclitaxel and Gemcitabine) vs Ibrutinib (Plus Nab-paclitaxel and Gemcitabine): serious adverse events | 127 of 212 | 112 of 208 | 420 | NCT02436668 | Trial comparisons |
| CO-1.01 vs Gemcitabine: serious adverse events | 82 of 179 | 82 of 181 | 360 | NCT01124786 | Trial comparisons |
| Ruxolitinib Plus Capecitabine vs Placebo Plus Capecitabine: serious adverse events | 94 of 153 | 83 of 154 | 307 | NCT02117479 | Trial comparisons |
| EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate | 2 of 108 | 2 of 110 | 218 | NCT03126435 | Trial comparisons |
| EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: deaths from any cause | 91 of 108 | 85 of 110 | 218 | NCT03126435 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006047/comparisons